Fenofibrate decreases the fibrinogen contents depending on its basal plasma levels in patients with hyperlipidemia

被引：0
|
作者：
Gurevich, VS [1 ]
Popov, YG [1 ]
Astashkina, TD [1 ]
Kasennova, NI [1 ]
Urasgildeeva, SA [1 ]
机构：
[1] INST CARDIOL,ST PETERSBURG,RUSSIA
来源：
ATHEROSCLEROSIS | 1997年 / 134卷 / 1-2期
关键词：
D O I：
10.1016/S0021-9150(97)88673-X
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：124 / 124
页数：1
相关论文
共 50 条
  • [1] Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia
    de la Serna, G
    Cadarso, C
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (02) : 166 - 172
  • [2] GLUCOSAMINOGLYCANS ADMINISTRATION DECREASES HIGH FIBRINOGEN PLASMA-LEVELS IN DIABETIC-PATIENTS
    CERIELLO, A
    QUATRARO, A
    ETTORRE, M
    MARCHI, E
    BARBANTI, M
    GIUGLIANO, D
    DIABETES NUTRITION & METABOLISM, 1993, 6 (04) : 203 - 206
  • [3] Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia
    Milionis, HJ
    Papakostas, J
    Kakafika, A
    Chasiotis, G
    Seferiadis, K
    Elisaf, MS
    JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (08): : 825 - 830
  • [4] Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of Fluvastatin or Fenofibrate
    Blann, AD
    Belgore, FM
    Constans, J
    Conri, C
    Lip, GYP
    AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (10): : 1160 - 1163
  • [5] Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: Reduction during atorvastatin and fenofibrate therapy
    Arca, Marcello
    Natoli, Silvia
    Micheletta, Fausta
    Riggi, Sara
    Di Angelantonio, Emanuele
    Montali, Anna
    Antonini, Teresa Maria
    Antonini, Roberto
    Diczfalusy, Ulf
    Iuliano, Luigi
    FREE RADICAL BIOLOGY AND MEDICINE, 2007, 42 (05) : 698 - 705
  • [6] Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome
    Jastrzebska, M
    Torbus-Lisiecka, B
    Pieczul-Mróz, J
    Chelstowski, K
    Kopciewicz, J
    Naruszewicz, M
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 1999, 19 (01) : 19 - 25
  • [7] Effects of fenofibrate therapy on plasma ubiquinol-10 and ubiquinone-10 levels in Japanese patients with hyperlipidemia and type 2 diabetes mellitus
    Asano, A
    Kobayashi, J
    Murase, Y
    Nohara, A
    Kawashiri, MA
    Inazu, A
    Shimizu, M
    Mabuchi, H
    PHARMACOTHERAPY, 2006, 26 (04): : 447 - 451
  • [8] The impact of plasma fibrinogen levels on patients with vulvar cancer
    Seebacher, Veronika
    Polterauer, Stephan
    Grimm, Christoph
    Tempfer, Clemens
    Hefler-Frischmuth, Katrin
    Reinthaller, Alexander
    Hefler, Lukas
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2012, 161 (01) : 88 - 91
  • [9] Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects
    Hsia, Chien-Hsun
    Shen, Ming-Ching
    Lin, Jen-Shiou
    Wen, Yao-Ke
    Hwang, Kai-Lin
    Cham, Thau-Ming
    Yang, Nae-Cherng
    NUTRITION RESEARCH, 2009, 29 (03) : 190 - 196
  • [10] Fenofibrate decreases plasma ceramide in type 2 diabetes patients: A novel marker of CVD?
    Croyal, M.
    Kaabia, Z.
    Leon, L.
    Ramin-Mangata, S.
    Baty, T.
    Fall, F.
    Billon-Crossouard, S.
    Aguesse, A.
    Hollstein, T.
    Sullivan, D. R.
    Nobecourt, E.
    Lambert, G.
    Krempf, M.
    DIABETES & METABOLISM, 2018, 44 (02) : 143 - 149
12345